Q-omics provides the consensus-scored ZNF586 profile across patient tissues and cancer cell-line models. ZNF586 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, ZNF586 is differentially expressed in 9, with the highest sampling consensus in THCA. Additionally, ZNF586 RNA expression shows 20,788 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and THCA as cancer lineages where ZNF586 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF586 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF586 survival associations across molecular data types. ZNF586 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF586 RNA expression–survival associations across cancer types. High ZNF586 expression shows unfavorable associations in ACC, ESCA, MESO and LGG, but favorable associations in BRCA and SCLC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for ZNF586 RNA expression.
This table summarizes ZNF586 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF586. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF586 shows lower tumor expression in THCA, KICH and LUAD and higher tumor expression in BRCA, CHOL and LIHC. The THCA box plot shows higher ZNF586 RNA expression in normal versus tumor tissue (log2 FC = −0.496, t-test p < 0.001).
This table shows molecular features associated with ZNF586 in patient tissues and cancer cell lines. In patient samples, ZNF586 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF586 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Leukemia.
